Five-Year Business Highlights

Principal Financial Data

Fiscal year
(millions of yen)
2018/3 2019/3 2020/3 2021/3 2022/3 2023/3 (forecast)
Net sales / Sales revenue 101,448 114,716 116,637 121,885 137,547 134,000
 Pharmaceuticals 87,416 100,223 101,643 106,478 120,650 115,000
 Functional food 14,031 14,492 14,994 15,406 16,897 19,000
Operating income 17,079 20,644 21,668 26,134 28,299 27,000
Ordinary income 17,451 21,540 22,442 26,760 29,773 -
Net income attributable to owners of the parent / Profit attributable to owners of the parent 12,953 16,302 16,866 20,702 23,044 21,500
Depreciation and amortization 2,773 3,418 3,468 3,550 2,933 5,200
Capital investment 2,811 1,242 2,500 2,583 4,264 8,500
R&D expenses 13,221 16,701 13,994 16,104 26,386 24,400
Total assets 155,887 168,763 175,017 197,028 210,052
Net assets 125,689 135,190 145,760 162,543 176,767

* We have voluntarily applied International Financial Reporting Standards (IFRS) to the consolidated financial statement in our annual securities report since the fiscal year ended March 2022. Therefore, our consolidated financial forecast for the fiscal year ending March 2023 is produced according to IFRS.

Net Sales

For the fiscal year ended March 2022, net sales were 137,547 million yen, an increase of 12.8% year on year. Factors that contributed to the increase include royalty income from overseas sales of Uptravi, a treatment for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), growth in domestic sales of new pharmaceutical products, and income from the sale of priority review vouchers issued by the U.S. Food and Drug Administration (FDA).

Operating income
 

Net income attributable to owners of the parent

Operating income was 28,299 million yen, an 8.3% increase year on year, and net income attributable to owners of the parent was 23,044 million yen, an 11.3% increase year on year, mainly due to a decrease in the ratio of cost to sales caused by the increase in sales and improvement of the sales mix.

R&D expenses

Principal Financial Indicators

Fiscal year (yen) 2018/3 2019/3 2020/3 2021/3 2022/3
Earnings per share (EPS) 192.31 242.04 250.42 307.37 342.14
Dividend per share 52 70 86 99 110
Equity ratio 80.5 80.0 83.1 82.4 84.0
Return on equity (ROE) 10.8 12.5 12.0 13.5 13.6
Payout ratio 27 28.9 34.3 32.2 32.2

EPS / ROE

  • Earnings per share (EPS)
  • Return on equity (ROE)

Dividend per share / Payout ratio

  • Dividend per share
  • Payout ratio

Cash Flows

Fiscal year (millions of yen) 2018/3 2019/3 2020/3 2021/3 2022/3
Cash flow from operating activities 6,719 15,310 12,737 21,388 16,018
Cash flow from investing activities △11,342 511 △2,339 △1,564 △6,359
Cash flow from financing activities △3,787 △3,708 △5,660 △6,199 △6,801

Long-term Chronological Data

View long-term chronological data from here.